Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 9/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909017 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL14979217 | 0.78 | SMN1; SMN2 (0.55) | MAP2K4SMN1; SMN2MAPK1MAPK6GSK3B | |
| SCHEMBL23914974 | 0.77 | MAP2K4 (0.45) | MAP2K4MAPK1MAPK6GSK3BITK | |
| SCHEMBL8205073 | 0.76 | SMN1; SMN2 (0.45) | MAP2K4SMN1; SMN2MAPTMAPK1GSK3B | |
| SCHEMBL14564361 | 0.76 | SMN1; SMN2 (0.55) | MAP2K4SMN1; SMN2MAPTMAPK1MAPK6 | |
| SCHEMBL22267604 | 0.75 | GSK3B (0.55) | MAP2K4SMN1; SMN2MAPTGSK3B | |
| SCHEMBL6016609 | 0.75 | SMN1; SMN2 (0.53) | MAP2K4SMN1; SMN2MAPTGSK3BCYP1A2 | |
| SCHEMBL14979221 | 0.74 | MAP2K4 (0.54) | MAP2K4MAPK1MAPK6GSK3BITK | |
| SCHEMBL5953156 | 0.73 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6ITK | |
| SCHEMBL15882110 | 0.72 | MAP2K4 (0.65) | MAP2K4SMN1; SMN2MAPTMAPK1MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | MAP2K4 4247/4885SMN1; SMN2 2920/4885MAPT 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.